Rapamycin & mTOR Inhibition
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
mTOR inhibition is one of the most robust lifespan-extension findings in animal models (NIA Interventions Testing Program, multiple species), but the only completed human RCT for longevity purposes (PEARL) was small, short (48 weeks), missed its primary endpoint, and did not measure lifespan, so human-specific longevity evidence remains preliminary.
Reference only. Not medical advice.
Rapamycin (sirolimus) is an FDA-approved immunosuppressant that inhibits mTORC1, a central nutrient-sensing signaling complex that regulates cell growth, protein synthesis, and autophagy. Reduced mTOR signaling is one of the most consistently replicated longevity-extending interventions across model organisms, including yeast, worms, flies, and mice, and the NIA Interventions Testing Program found rapamycin extended median mouse lifespan by roughly 9 to 26 percent depending on dose, sex, and when treatment began, including when started in relatively old mice. This animal evidence is considered unusually strong and reproducible compared to most other candidate longevity drugs. Human evidence is much earlier stage. Rapamycin has decades of safety data from transplant medicine, but at continuous, higher immunosuppressive doses that carry known risks including infection susceptibility, impaired wound healing, mouth ulcers, elevated lipids, and glucose intolerance. Longevity researchers hypothesize that intermittent, lower, weekly dosing may capture benefits attributed to mTORC1 inhibition while sparing mTORC2, reducing metabolic side effects, though this remains a hypothesis rather than an established finding. The PEARL trial, a 48-week randomized, placebo-controlled study of about 114 healthy adults aged 50 to 85 taking low weekly doses (5 or 10 mg compounded rapamycin), found a comparable adverse-event profile to placebo and some secondary improvements in lean tissue mass and self-reported pain in a subgroup, but no significant change in its primary outcome (visceral fat) and a discovery that the compounded formulation used had markedly lower bioavailability than commercial rapamycin, complicating interpretation. No trial has measured effects on human lifespan, and rapamycin is not FDA-approved for any anti-aging indication. Current status is that off-label, self-directed use for longevity purposes is occurring within a community of physicians and patients despite the absence of large controlled human outcome data, which is a significant caveat and an active point of debate among aging researchers, some of whom caution against extrapolating from short-term biomarker changes or from transplant-dose safety data to long-term low-dose use in healthy people.
Rapamycin (sirolimus) is an FDA-approved immunosuppressant that inhibits mTORC1, a central nutrient-sensing signaling complex that regulates cell growth, protein synthesis, and autophagy.
Safety in detail
At immunosuppressive transplant doses, known risks include infection, impaired wound healing, mouth sores, and dyslipidemia; long-term safety of low-dose intermittent regimens in healthy adults for longevity purposes has not been established in controlled trials.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Rapamycin was isolated in the mid-1960s to 1970s from Streptomyces hygroscopicus, a soil bacterium collected during a 1964 Canadian medical expedition to Easter Island (Rapa Nui), from which the compound takes its name; it was first studied as an antifungal agent. In the 1990s its immunosuppressive properties were characterized and it was developed by Wyeth as sirolimus, approved by the FDA in 1999 to prevent organ transplant rejection under the brand name Rapamune. Its mechanism, inhibition of the mTOR (mechanistic/mammalian target of rapamycin) kinase complex, was discovered through the 1990s research that gave the pathway its name. The pivot toward longevity research followed a 2009 NIA Interventions Testing Program study showing rapamycin extended median lifespan in genetically heterogeneous mice even when started late in life, the first pharmacological intervention shown to do so in that rigorous multi-site testing framework, which spurred a wave of research into intermittent, lower-dose regimens intended to preserve benefits while reducing the immunosuppressive and metabolic side effects seen at transplant doses.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Rapamycin & mTOR Inhibition. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.